ResMed's Q1 Results
ResMed's first-quarter result broadly met market expectations, with rising margins and potential for further capital management.
However, this was negated by US import tariff ambiguity. The company's operating earnings and gross margin exceeded market expectations, driven by growth across sleep apnoea devices, masks, and software portfolio.
- Margins outperformed forecasts
- SaaS segment proved slightly softer
Management's outlook guidance remains unchanged, with ResMed delivering a quarter in line with consensus forecasts for revenue and earnings, posting year-on-year core EPS growth of 16%.
ResMed's first-quarter result broadly met market expectations, though rising margins and potential for further capital management have been negated by US import tariff ambiguity.
Author's summary: ResMed's Q1 results met expectations despite tariff uncertainty.